Mohammad Nafeli Shahrestani: CXCL10 Associated With Increased Long-Term Risk of Ischemic Stroke
Mohammad Nafeli Shahrestani, Postdoctoral Research Fellow at University of Miami Evelyn F. McKnight Brain Institute, Medical Doctor at Private Practice, shared a post on LinkedIn about a recent article he and his colleagues co-authored, published in Translational Stroke Research, adding:
“I’m glad to share that our new article has been published in Translational Stroke Research. We performed a large-scale but immune-focused screening of plasma immune markers in the Northern Manhattan Study (NOMAS).
Machine learning-assisted data reduction identified C-X-C motif chemokines as candidate markers of stroke risk. One standard deviation (SD) increase in baseline plasma C-X-C motif chemokine ligand 10 (CXCL10) was associated with a 20% greater risk of all-cause and ischemic stroke over more than a decade of follow-up.
This association was independent of sociodemographic factors, cardiovascular risk factors, comorbidities, MRI-measured white matter disease, and kidney function. The results were internally validated.
CXCL10, a chemokine induced by interferon gamma (IFN-γ), may play a direct role in stroke pathogenesis.
Our findings suggest that CXCL10 is a marker of cerebrovascular disease and may add prognostic value when integrated with clinical, imaging, and laboratory assessments. CXCL10 may also be a target for pharmacological intervention to preserve cerebrovascular health.
I am grateful to all NOMAS participants, my mentors, and my co-authors.”
Title: Chemokine CXCL10 and Incident Stroke Risk in the Northern Manhattan Study
Authors: Mohammad Nafeli Shahrestani, Christian Agudelo, Hannah Gardener, Emir Veledar, Jose A Santiago, Marco R Di Tullio, David Della-Morte, Botagoz Aimagambetova, Jose Gutierrez, Mady Hornig, Mitchell S V Elkind, Hyun Song, Clinton B Wright, Sarah E Tom, Tatjana Rundek

Stay updated on all scientific advances with Hemostasis Today.
-
Nov 14, 2026, 10:00Benjamin Tur: Putting Iron Deficiency Anemia on the Global Agenda at the Paris Peace Forum’s Child Summit
-
Nov 14, 2026, 09:48Jack Shuang Hou: FDA Approves Bayer’s Sunharbo – First Factor XIa Inhibitor for Secondary Stroke Prevention
-
Nov 14, 2026, 09:42Samwel Mikaye: What Every Patient Should Know About DVT Symptoms and Treatment
-
Nov 14, 2026, 09:37Chronic Preoperative Corticosteroid Use and Postoperative Venous Thromboembolism Risk – Thrombosis and Haemostasis Journal
-
Nov 14, 2026, 09:30Ney Carter Borges: Vulnerable Plaque – Imaging and Clinical Significance
-
Nov 14, 2026, 09:25Carmelo Raffo: How Much Antithrombotic Therapy is Truly Necessary after LAAC?
-
Nov 14, 2026, 09:19Mary Cushman: Excellent to Have Jordan Shavit Visit Us for a Virtual Lab Meeting Today
-
Nov 14, 2026, 09:15Chancellor Donald: Heading to ASH 2026 in New Orleans? Let’s Connect on Faculty Opportunities at Tulane
-
Nov 14, 2026, 09:11Sajja Venkatesh: FDA Approved Asundexian, the First Factor XIa Inhibitor